Hims & Hers Acquires Eucalyptus, Expanding into Japan and Australia

Key Facts

1Hims & Hers Health completed the acquisition of Eucalyptus, the parent company of brands including Juniper and Pilot.

2The acquisition marks the company's official entry into the Japanese and Australian markets, while strengthening its presence in Canada and Germany.

3The deal aims to scale the company's consumer health platform, particularly in the weight management sector.

In a move reflecting the accelerating expansion within the digital health sector, Hims & Hers Health has completed the acquisition of Eucalyptus, the parent company of brands including Juniper and Pilot. This acquisition marks the company's official entry into the Japanese and Australian markets while strengthening its footprint in Canada and Germany. The deal aims to scale the company's consumer health platform, particularly within the rapidly growing weight management sector.

This expansion comes amid intensifying competition with peers like Ro and LifeMD in the telehealth space, as Hims & Hers seeks to leverage Eucalyptus's clinical infrastructure. According to market data, the weight loss medication (GLP-1) segment has become a primary growth driver for health-tech firms, with Hims & Hers previously reporting a 46% revenue increase in Q1 2024 (per historical earnings reports). The acquisition is viewed as a strategic step toward becoming the world's largest consumer health platform.

Regarding stock performance, HIMS remains at key technical levels as investors monitor the integration of Eucalyptus operations across new geographies. On the economic front, recent data from Australia included the Economic Bulletin release on May 28, 2026, providing broader context for consumer conditions in one of the company's new primary markets. Market participants will look to upcoming earnings calls to assess the immediate financial impact of this international scale-up.